Actively Recruiting
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Led by Ottawa Hospital Research Institute · Updated on 2026-01-30
20
Participants Needed
2
Research Sites
399 weeks
Total Duration
On this page
Sponsors
O
Ottawa Hospital Research Institute
Lead Sponsor
T
The Canadian College of Naturopathic Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care. Too many clinical trials focus on single agent therapies, rather than broad multi-faceted individualized and integrative care interventions that are used in real world settings. The Thoracic POISE project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery.
CONDITIONS
Official Title
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults eligible for complete resection of lung, gastric or esophageal cancer
You will not qualify if you...
- Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours
- Any wedge resections of lung cancer
- History of cancer with active treatment in the last 3 years (not including superficial bladder cancer or non-melanoma skin cancer)
- Patients currently receiving care guided by an ND or who have previously seen an ND in the last 3 months
- Pregnant or breastfeeding women
- Any reason which, in the opinion of the Principal Investigator (or delegate), would prevent the subject from participating in the study
- Use of an investigational drug or participation in an investigational study within 30 days prior to starting the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
2
Michael Garron Hospital
Toronto, Ontario, Canada, M4C 3E7
Actively Recruiting
Research Team
A
Anna Fazekas, MA, CCRP
CONTACT
M
Mark Legacy, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here